Dr. Benjamin Hibbert, MD
Claim this profileOttawa Heart Institute
Affiliated Hospitals
Ottawa Heart Institute
University Of Ottawa Heart Institute
Clinical Trials Benjamin Hibbert, MD is currently running
Left Atrial Appendage Occlusion vs. NOAC
for Atrial Fibrillation
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
Recruiting
1 award
N/A
8 criteria
Blood Thinners
for Atrial Fibrillation
Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others. Not only can it ruin one's life, but it can also be fatal. A stroke occurs when blood flow to the brain is blocked by a clot, depriving brain cells of oxygen. In people with atrial fibrillation, blood flow is sluggish in the top chambers of the heart, and blood clots can form there. When a piece of a clot breaks off, it can travel to the brain and cause a stroke. That's where blood thinners come in. Blood thinners, or anticoagulants, decrease the chances of blood clots forming in the heart, reducing the risk of stroke. Studies show that blood thinners are highly effective at reducing the risk of stroke by up to 95%. The conventional blood thinner is warfarin, taken by mouth. Warfarin requires regular blood tests to make sure a patient getting the correct dose. The patient also may have to avoid certain foods since the medication can interact with them. Newer blood thinners, known as direct-oral anticoagulants (DOACs) are available, which do not require regular blood tests and do not interact with foods. Two of the new blood thinners are called rivaroxaban and apixaban. Like warfarin, they can be taken by mouth, and studies have shown them to be as effective as warfarin. Both rivaroxaban and apixaban have been approved for stroke prevention in AF by Health Canada. However, there have been no direct head-to-head comparisons of these two anticoagulants, meaning comparative safety data is not available. Increasing use of DOACs for stroke prevention in AF and patient values around bleeding highlight the need for a comparison trial to ensure patients receive the anticoagulant with the greatest balance of benefit to potential harm. The trial is to assess bleeding rates and superiority of using apixaban versus rivaroxaban in patients with non-valvular atrial fibrillation.
Recruiting
3 awards
Phase 4
2 criteria
More about Benjamin Hibbert, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Benjamin Hibbert, MD has experience with
- Tendyne Mitral Valve System
- MitraClip System
- Apixaban
- Rivaroxaban
- Edwards Transcatheter Atrial Shunt System
- MitraClip™ Device Implantation
Breakdown of trials Benjamin Hibbert, MD has run
Mitral Valve Regurgitation
Atrial Fibrillation
Mitral Regurgitation
Bleeding
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Benjamin Hibbert, MD specialize in?
Benjamin Hibbert, MD focuses on Mitral Valve Regurgitation and Atrial Fibrillation. In particular, much of their work with Mitral Valve Regurgitation has involved Stage III patients, or patients who are undergoing treatment.
Is Benjamin Hibbert, MD currently recruiting for clinical trials?
Yes, Benjamin Hibbert, MD is currently recruiting for 3 clinical trials in Ottawa Ontario. If you're interested in participating, you should apply.
Are there any treatments that Benjamin Hibbert, MD has studied deeply?
Yes, Benjamin Hibbert, MD has studied treatments such as Tendyne Mitral Valve System, MitraClip System, Apixaban.
What is the best way to schedule an appointment with Benjamin Hibbert, MD?
Apply for one of the trials that Benjamin Hibbert, MD is conducting.
What is the office address of Benjamin Hibbert, MD?
The office of Benjamin Hibbert, MD is located at: Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7 Canada. This is the address for their practice at the Ottawa Heart Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.